File downloaded on 2026-11-22
Source URL: https://medicines.health.europa.eu/veterinary/en/600000055718

Nobivac DHP Live Vet. pulver og solvens til injektionsvæske, suspension

Authorised

- Canine adenovirus 2, strain Manhattan LPV3, Live
- Canine parvovirus, strain 154, Live
- Canine distemper virus, strain Onderstepoort, Live
- Canine adenovirus 2, strain Manhattan LPV3, Live
- Canine parvovirus, strain 154, Live
- Canine distemper virus, strain Onderstepoort, Live

Product identification

Medicine name:
Nobivac DHP Live Vet. pulver og solvens til injektionsvæske, suspension

Active substance:
Canine adenovirus 2, strain Manhattan LPV3, Live

Canine parvovirus, strain 154, Live

Canine distemper virus, strain Onderstepoort, Live

Canine adenovirus 2, strain Manhattan LPV3, Live

Canine parvovirus, strain 154, Live

Canine distemper virus, strain Onderstepoort, Live

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Canine adenovirus 2, strain Manhattan LPV3, Live
10000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Canine parvovirus, strain 154, Live
1000000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Canine distemper virus, strain Onderstepoort, Live
10000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Canine adenovirus 2, strain Manhattan LPV3, Live
10000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Canine parvovirus, strain 154, Live
1000000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Canine distemper virus, strain Onderstepoort, Live
10000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Pharmaceutical form:
Powder and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AD02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Denmark

Available in:
Denmark

Package description:

Available only in Danish
Available only in Danish

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
11/05/1993

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
Danish Medicines Agency

Authorisation number:
14110

Date of authorisation status change:
11/05/1993

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.